T Cells
T cells are immune cells that fight infections, as well as cancer cells.
EPKINLY is used to treat certain types of diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) that returned or didn't respond after receiving 2 or more treatments. EPKINLY is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY.
EPKINLY is not an infusion, chemotherapy, or stem cell therapy. It is a bispecific antibody that harnesses the power of your own immune system to fight cancer.
given as an injection; it's not an infusion, chemotherapy, or stem cell therapy.
a treatment that may be given at a location that is able to administer EPKINLY, such as your oncologist’s office or a nearby outpatient center.
a treatment you can start as soon as you and your doctor are ready.
Ask your doctor if EPKINLY is right for you.
EPKINLY is designed to target 2 types of cells in your body—T cells and B cells.
Select each tile to learn more
T Cells
T cells are immune cells that fight infections, as well as cancer cells.
B Cells
B cells are another type of immune cell. In DLBCL and FL, some B cells can become cancerous and grow uncontrollably.
How EPKINLY Works
EPKINLY works by attaching to both your T cells and B cells, binding them together so that the T cells can attack and destroy B cells.
Get more information about treatment with EPKINLY.
See how EPKINLY worked for others.
Explore clinical trial results in:
See how EPKINLY has worked for others.
EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, or follicular lymphoma (FL) that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.
People with DLBCL or high-grade B-cell lymphoma should be hospitalized for 24 hours after receiving their first full dose of EPKINLY on day 15 of cycle 1 due to the risk of CRS and neurologic problems.
Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away.
EPKINLY can cause other serious side effects, including:
Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.
Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.
In DLBCL or high-grade B-cell lymphoma, the most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea. The most common severe abnormal laboratory test results include decreased white blood cells, decreased red blood cells, and decreased platelets.
In follicular lymphoma the most common side effects of EPKINLY include injection site reactions, CRS, COVID-19, tiredness, upper respiratory tract infections, muscle and bone pain, rash, diarrhea, fever, cough, and headache. The most common severe abnormal laboratory test results include decreased white blood cells and decreased red blood cells.
These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1‑855‑443‑6622).
Please see Medication Guide, including Important Warnings.
COM-US-EPK-0000771